This study evaluates the hemostatic properties of tantalum-containing mesoporous bioactive glasses (Ta-MBGs) through a suite of in-vitro methods: hemolysis percentage, zeta potential, blood coagulation assays (Activated Partial Thromboplastin Time – APTT and Prothrombin Time - PT) and cytotoxicity tests. Five compositions of Ta-MBG, with x mol% Ta2O5 added to the glass series (80-x)SiO2-15CaO-5P2O5-xTa2O5 where x=0 (0Ta), x=0.5 (0.5Ta), x=1 (1Ta), x=5 (5Ta), and x=10 (10Ta) mol%, were synthesised. The hemostatic potential of all the Ta-MBGs was confirmed by their negative zeta potential (–23 to –31 mV), which enhances the intrinsic pathway of blood coagulation. The hemolysis percentages of all Ta-MBGs except 10Ta showed statistically significant reductions compared to the same experiments carried out both in the absence of a sample (‘no treatment’ group) and in the presence of 10Ta. These observations validate the consideration of Ta-MBGs as hemostatic agents as they do not cause significant lysis of red blood cells. Cytotoxicity analysis revealed that Ta-MBGs had no effect on bovine fibroblast viability. Furthermore, a reduction in both APTT (a test to evaluate the intrinsic pathway of coagulation) and PT (a test to evaluate the extrinsic pathway) signified enhancement of hemostasis: 5Ta caused a significant reduction in APTT compared to ‘no treatment’, 1Ta and 10Ta and a significant reduction in PT compared to 0Ta. Therefore, we conclude that 5mol% of Ta optimised the hemostatic properties of these mesoporous bioactive glasses.
WangYGallantRCNiH.Extracellular matrix proteins in the regulation of thrombus formation. Curr Opin Hematol2016;
23: 280–287.
2.
GeddingsJMackmanN.New players in haemostasis and thrombosis.Thromb Haemost2014;
111: 570–574.
3.
WangYRehemanASpringC, et al.
Plasma fibronectin supports hemostasis and regulates thrombosis.J Clin Invest2014;
124: 4281–4293.
4.
NiHFreedmanJ.Platelets in hemostasis and thrombosis: role of integrins and their ligands. Transfus Apher Sci2003;
28: 257–264.
5.
XuXRZhangDOswaldBE, et al.
Platelets are versatile cells: new discoveries in hemostasis, thrombosis, immune responses, tumor metastasis and beyond.Crit Rev Clin Lab Sci2016;
53: 409–430.
6.
AdairBDAlonsoJLvan AgthovenJ, et al.
Structure-guided design of pure orthosteric inhibitors of αIIbβ3 that prevent thrombosis but preserve hemostasis.Nat Commun2020;
11: 398.
7.
DunneESpringCMRehemanA, et al.
Cadherin 6 has a functional role in platelet aggregation and thrombus formation.Arterioscler Thromb Vasc Biol2012;
32: 1724–1731.
8.
RehemanATasneemSNiH, et al.
Mice with deleted multimerin 1 and α-synuclein genes have impaired platelet adhesion and impaired thrombus formation that is corrected by multimerin 1. Thromb Res2010;
125: e177–e183.
9.
RehemanAYangHZhuG, et al.
Plasma fibronectin depletion enhances platelet aggregation and thrombus formation in mice lacking fibrinogen and von Willebrand factor.Blood2009;
113: 1809–1817.
10.
YangHRehemanAChenP, et al.
Fibrinogen and von Willebrand factor-independent platelet aggregation in vitro and in vivo.J Thromb Haemost2006;
4: 2230–2237.
11.
NiHYuenPSTPapaliaJM, et al.
Plasma fibronectin promotes thrombus growth and stability in injured arterioles. Proc Natl Acad Sci U S A2003;
100: 2415–2419.
12.
HoffmanM.Remodeling the blood coagulation cascade. J Thromb Thrombolysis2004;
16: 17–20.
13.
SperlingCFischerMMaitzMF, et al.
Blood coagulation on biomaterials requires the combination of distinct activation processes.Biomaterials2009;
30: 4447–4456.
14.
GuiTRehemanAFunkhouserWK, et al.
In vivo response to vascular injury in the absence of factor IX: examination in factor IX knockout mice.Thromb Res2007;
121: 225–234.
15.
ByrnesJRDuvalCWangY, et al.
Factor XIIIa-dependent retention of red blood cells in clots is mediated by fibrin α-chain crosslinking.Blood2015;
126: 1940–1948.
16.
XuXRGallantRCNiH.Platelets, immune-mediated thrombocytopenias, and fetal hemorrhage. Thromb Res2016;
141: S76–S79.
17.
GuytonACHallJE. Hemostasis and blood coagulation. In: Textbook of medical physiology. Philadelphia: Elsevier Inc., 2006, pp. 457–468.
18.
PourshahrestaniSZeimaranEDjordjevicI, et al.
Inorganic hemostats: the state-of-the-art and recent advances.Mater Sci Eng C2016;
58: 1255–1268.
19.
HoweNCherpelisB.Obtaining rapid and effective hemostasis: part I. Update and review of topical hemostatic agents.J Am Acad Dermatol2013;
69: 659.e1–659.e17.
20.
PourshahrestaniSZeimaranEKadriNA, et al.
Gallium-containing mesoporous bioactive glass with potent hemostatic activity and antibacterial efficacy.J Mater Chem B2016;
4: 71–86.
21.
OstomelTAShiQStoimenovPK, et al.
Metal oxide surface charge mediated hemostasis. Langmuir2007;
23: 11233–11238.
22.
KaurGPandeyOPSinghK, et al.
A review of bioactive glasses: their structure, properties, fabrication and apatite formation.J Biomed Mater Res Part A2014;
102: 254–274.
23.
MendoncaARahmanMSAlhalawaniA, et al.
The effect of tantalum incorporation on the physical and chemical properties of ternary silicon–calcium–phosphorous mesoporous bioactive glasses.J Biomed Mater Res Part B Appl Biomater2019; 107: 2229–2237.
24.
NagrathMAlhalawaniARahimnejad YazdiA, et al.
Bioactive glass fiber fabrication via a combination of sol-gel process with electro-spinning technique. Mater Sci Eng C2019;
101: 521–538.
25.
HoppeAGüldalNSBoccacciniAR.A review of the biological response to ionic dissolution products from bioactive glasses and glass-ceramics.Biomaterials2011;
32: 2757–2774.
26.
Olson CT and Hoffmann RW. Tantalum oxide composition. US Patent 2,491,416, USA, December 13, 1949.
27.
AlhalawaniAMMehrvarCStoneW, et al.
A novel tantalum-containing bioglass. Part II. Development of a bioadhesive for sternal fixation and repair.Mater Sci Eng C2017;
71: 401–411.
28.
HuangHLTsaiMTLinYJ, et al.
Antibacterial and biological characteristics of tantalum oxide coated titanium pretreated by plasma electrolytic oxidation. Thin Solid Films2019;
688: 137268.
29.
YanXYuCZhouX, et al.
Highly ordered mesoporous bioactive glasses with superior in vitro bone-forming bioactivities. Angew Chemie Int Ed2004;
43: 5980–5984.
30.
DaiCLiuCWeiJ, et al.
Molecular imprinted macroporous chitosan coated mesoporous silica xerogels for hemorrhage control.Biomaterials2010;
31: 7620–7630.
31.
DaiCYuanYLiuC, et al.
Degradable, antibacterial silver exchanged mesoporous silica spheres for hemorrhage control.Biomaterials2009;
30: 5364–5375.
32.
ISO 10993-5. Biological evaluation of medical devices-Part 5: tests for in vitro cytotoxicity.
33.
MatterMTStarsichFGalliM, et al.
Developing a tissue glue by engineering the adhesive and hemostatic properties of metal oxide nanoparticles.Nanoscale2017;
9: 8418–8426.
34.
LongMZhangYHuangP, et al.
Emerging nanoclay composite for effective hemostasis. Adv Funct Mater2018;
28: 1–9.
35.
OstomelTAShiQTsungCK, et al.
Spherical bioactive glass with enhanced rates of hydroxyapatite deposition and hemostatic activity. Small2006;
2: 1261–1265.
36.
DavieEWRattnoffOD.Waterfall sequence for intrinsic blood clotting. J Sci1964;
145: 1310–1312.
37.
JonesJR.Bio-glasses an introduction.
Chichester:
A John Wiley & Sons, 2012.
38.
SerraJGonzálezPListeS, et al.
FTIR and XPS studies of bioactive silica based glasses. J Non Cryst Solids2003;
332: 20–27.
39.
DoostmohammadiAMonshiASalehiR, et al.
Bioactive glass nanoparticles with negative zeta potential. Ceram Int2011;
37: 2311–2316.
40.
BakerSESawvelAMZhengN, et al.
Controlling bioprocesses with inorganic surfaces: layered clay hemostatic agents. Chem Mater2007;
19: 4390–4392.
41.
WuXWeiJLuX, et al.
Chemical characteristics and hemostatic performances of ordered mesoporous calcium-doped silica xerogels. Biomed Mater;
5: 035006.
RoachPFarrarDPerryCC.Surface tailoring for controlled protein adsorption: effect of topography at the nanometer scale and chemistry. J Am Chem Soc2006;
128: 3939–3945.
44.
PourshahrestaniSKadriNAZeimaranE, et al.
Well-ordered mesoporous silica and bioactive glasses: promise for improved hemostasis.Biomater Sci2019;
7: 31–50.
